small molecule

ZEMDRI

PLAZOMICIN SULFATE

Loss of exclusivityJune 2032latest FDA-listed patent expiry

CompanyCipla →View the full company profile on CliffBio

Drug detail

Brand name	ZEMDRI
Active ingredient	PLAZOMICIN SULFATE
Strength	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)
Dosage form	SOLUTION
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	June 2018
Marketing status	DISCN

Listed patents

Patent	Expires	Type
8383596	June 2032	substance
9688711	November 2028	substance
9266919	November 2028	use U-2328
8822424	November 2028	product

Regulatory exclusivity

Code	Expires
GAIN	June 2028
NCE	June 2023

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Cipla